Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.
Last trade$6.96
Day change+$0.175 (+2.58%)
Day range$6.71 – $6.98
Volume1,516,625
Market cap$1.04B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.04B
Price / earnings
—
Price / book
48.8×
Price / sales
1.24×
EV / sales
1.79×
EV / EBITDA
28.47×
Profitability
Earnings per share
-$0.57
Return on assets
-10.91%
Return on equity
-407.9%
Dividend yield
0%
Liquidity and leverage
Debt / equity
25.68×
Current ratio
2.36×
Quick ratio
1.22×
Cash ratio
0.44×
Cash flow
Price / cash flow
16.95×
Price / free cash flow
339.07×
Free cash flow
$3.07M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ATEC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$221.17M
$213.51M
$192.11M
$212.93M
$196.5M
$185.54M
$169.18M
$176.79M
Cost of revenue
$62.93M
$59.42M
$55.63M
$63.44M
$59.2M
$56.44M
$53.18M
$55.21M
Gross profit
$158.25M
$154.1M
$136.48M
$149.49M
$137.3M
$129.1M
$116M
$121.59M
Selling, general and administrative
$132.51M
$134M
$137.06M
$128.7M
$124.3M
$118.51M
$127.02M
$114.66M
Research and development
$18M
$18.17M
$17.56M
$22.28M
$18.68M
$18.28M
$16.58M
$23.24M
Total operating expenses
$155M
$156.01M
$159.06M
$158.31M
$153.23M
$142.19M
$160.29M
$145.41M
Operating income
$3.25M
-$1.91M
-$22.58M
-$8.82M
-$15.93M
-$13.09M
-$44.29M
-$23.82M
Interest expense
-$10.62M
-$10.96M
-$11.72M
-$12.89M
-$12.88M
-$12.31M
-$7.84M
-$7.15M
Income before taxes
-$7.47M
-$25.63M
-$33.86M
-$21.75M
-$28.5M
-$41.18M
-$51.97M
-$32.89M
Income taxes
-$1.99M
$156K
$50K
-$18K
$74K
-$37K
-$64K
$441K
Net income
-$5.47M
-$25.78M
-$33.91M
-$21.73M
-$28.58M
-$41.14M
-$51.91M
-$33.33M
Net income attributable to common shareholders
-$5.47M
-$25.78M
-$33.91M
-$21.73M
-$28.58M
-$41.14M
-$51.91M
-$33.33M
EBITDA
$24.3M
$17.8M
-$2.92M
$13.74M
$9.74M
$7.84M
-$11.8M
-$1.03M
Basic earnings per share
-$0.03
-$0.16
-$0.22
-$0.14
-$0.19
-$0.27
-$0.35
-$0.23
Diluted earnings per share
-$0.03
-$0.16
-$0.22
-$0.14
-$0.19
-$0.27
-$0.35
-$0.23
Recent news
Company coverage with links to the original publishers.
Alphatec (ATEC) reported quarterly earnings of $0.09 per share, missing the consensus estimate of $0.11, with revenues also falling short of expectations. The stock has declined 45.6% year-to-date and carries a Zacks Rank #3 (Hold) rating. The Medical-Instruments industry ranks in the bottom 40% of Zacks industries, suggesting broader sector weakness.
Alphatec Holdings CEO Miles Patrick purchased approximately 115,000 shares worth $1 million at a weighted average price of $8.81 per share on September 10, 2026. This insider buy increased his total beneficial ownership to 6.2 million shares worth $54.41 million. The article interprets this as a bullish signal, noting that insider purchases typically indicate confidence in future stock price appreciation. The company reported strong Q2 results with 15% sales growth and expanding surgeon adoption of its spinal surgery solutions.
Law firm Bragar Eagel & Squire is investigating Alphatec Holdings for potential federal securities law violations following the company's May 5, 2026 earnings miss. Alphatec reported lower-than-expected Q1 2026 revenue, reduced full-year EOS revenue guidance, and disclosed unfulfilled unit commitments due to installation timing challenges. The stock price declined following the announcement.
The Schall Law Firm is investigating Alphatec Holdings for potential securities fraud following the company's May 5, 2026 Q1 earnings report, which revealed missed revenue estimates, lower deliveries than prior year, and reduced full-year 2026 guidance. The stock fell 31.7% on May 6, 2026, after the company admitted to failing to fulfill committed unit deliveries.
The Law Offices of Frank R. Cruz is investigating Alphatec Holdings for potential federal securities law violations. On May 5, 2026, Alphatec reported Q1 2026 results that missed revenue consensus estimates, with lower deliveries and reduced full-year EOS revenue outlook. The company cited installation timing challenges and unfulfilled unit commitments. The stock fell 31.7% to $6.99 on May 6, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.